Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum in diffuse cutaneous systemic sclerosis
NCT03398837Phase 3Terminated
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Dec 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc) (3 arms), sponsored by Corbus Pharmaceuticals Holdings, Inc. Primary endpoint: American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis at 52 weeks. Started Dec 2017; status: terminated.
02
Drugs
lenabasum
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT03398837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398837.